Effect of Nrf2-ARE pathway in the heart ischemic injury

Abstract

CLC Number:

XU Yuan-qing, HE Hai-bo, ZHANG Chang-cheng, WANG Hong-wu, YUAN Ding. Effect of Nrf₂-ARE pathway in the heart ischemic injury[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(6): 695-698.

References

[1] Scolletta S, Biagioli B. Energetic myocardial metabolism and oxidative stress: Let's make them our friends in the fight against heart failure [J]. Biomed Pharmacother, 2010, 64 (3):203-207.
[2] 刘晓平. 癌症预防中的 Keap1-Nrf₂-ARE通路[J]. 中国临床药理学与治疗学, 2008, 13 (6): 716-720.
[3] Zhao CR, Gao ZH, Qu XJ. Nrf₂-ARE signaling pathway and natural products for cancer chemoprevention [J]. Cancer Epidemiol, 2010, 34 (5):523-533.
[4] Wang W, Jaiswal AK. Nuclear factor Nrf₂ and antioxidant response element regulate NRH:quinine oxidoreductase 2 (NQO2) gene expression and antioxidant induction [J]. Free Radic Biol Med, 2006, 40 (7):1119-1130.
[5] 朱晓洁, 梁飞, 王秀宏, 等. 钴原卟啉对 H9C2心肌细胞缺氧/复氧损伤的保护作用[J].中国药理学通报, 2009,25 (3):352-356.
[6] Li J, Ichikawa T, Jin Y, et al. An essential role of Nrf₂ in American ginseng-mediated anti-oxidative actions in cardiomyocytes [J]. J Ethnopharmacol, 2010, 130 (2): 222-230.
[7] Huerta-Olvera SG, Macías-Barragán J, Ramos-Márquez ME, et al. Alpha-lipoic acid regulates heme oxygenase gene expression and nuclear Nrf₂ activation as a mechanism of protection against arsenic exposure in HepG₂ cells [J]. Environmental Toxicol Pharmacol, 2010, 29 (2): 144-149.
[8] Wang X, Ye XL, Liu R, et al. Antioxidant activities of oleanolic acid in vitro: Possible role of Nrf₂ and MAP kinases [J]. Chem Biol Interact, 2010, 184 (3):328-337.
[9] Tripathi DN, Jena GB. Astaxanthin intervention ameliorates cyclophosphamide-induced oxidative stress, DNA damage and early hepatocarcinogenesis in rat: Role of Nrf₂, p53, p38 and phase-II enzymes [J]. Mutat Res, 2010, 696 (1): 69-80.
[10] Wang X, Hai CX, Liang X, et al. The protective effects of Acanthopanax senticosus Harms aqueous extracts against oxidative stress: Role of Nrf₂ and antioxidant enzymes [J]. J Ethnopharmacol, 2010,127 (2): 424-432.
[11] Sahin K, Tuzcu M, Gencoglu H, et al. Epigallocatechin-3-gallate activates Nrf₂/HO-1 signaling pathway in cisplatin-induced nephrotoxicity in rats [J]. Life Sci, 2010, 87 (7/8):240-245.
[12] Sahin K, Tuzcu M, Sahin N, et al. Nrf₂/HO-1 signaling pathway may be the prime target for chemoprevention of cisplatin-induced nephrotoxicity by lycopene[J]. Food Chem Toxicol, 2010, 48 (10): 2670-2674.
[13] Pi JB, Zhang Q, Fu JQ, et al. ROS signaling, oxidative stress and Nrf₂ in pancreatic beta-cell function [J]. Toxicol Appl Pharmacol, 2010, 244 (1):77-83.
[14] Safdar A, deBeer J, Tarnopolsky MA. Dysfunctional Nrf₂-Keap1 redox signaling in skeletal muscle of the sedentary old [J]. Free Radic Biol & Med, 2010, 49(10):1487-1493.
[15] Pedrosa AM, Faine LA, Grosso DM, et al. Electronegative LDL induction of apoptosis in macrophages: Involvement of Nrf₂ [J]. Biochimi Biophys Acta, 2010, 1801(1): 430-437.
[16] Zhang Y, Sano M, Shinmura K, et al. 4-Hydroxy-2-nonenal protects against cardiac ischemia-reperfusion injury via the Nrf₂-dependent pathway [J]. J Mol Cell Cardiol, 2010,49 (4): 576-586.
[17] Khanderao GD, Varadharaj S, Kannan S, et al. TNF-α activates Nrf₂/ARE signaling and promotes GSH synthesis in HL-1 cardiomyocytes [J].Free Rad biomed, 2010,10:361.
[18] He X, Kan H, Cai L, et al. Nrf₂ is critical in defense against high glucose-induced oxidative damage in cardiomyocytes [J]. J Mol Cell Cardiol, 2009, 46 (1):47-58.
[19] Zhua H, Itoh K, Yamamoto M, et al. Role of Nrf₂ signaling in regulation of antioxidants and phase-enzymes in cardiac fibroblasts: Protection against reactive oxygen and nitrogen species-induced cell injury[J]. FEBS Lett, 2005, 579 (14): 3029-3036.

Effect of Nrf₂-ARE pathway in the heart ischemic injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CAO Xuefen, LENG Yufang, HAN Xiaoxia, HOU Xiaoyu, LYU Xingjiao, Janvier NIBARUTA. Tetramethylpyrazine protected against intestinal ischemia-reperfusion injury induced pyroptosis by inhibiting NLRP3 inflammasome activation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1201-1208.
[2]	WANG Jian, SUN Yongdong, ZHOU Xingwei, LIU Lei, CHEN Long, TONG Xingke, ZHU Jiali. Baicalein promotes laryngeal cancer cell death and inhibits invasion via miR-125b-5p/IRF4 axis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1209-1218.
[3]	ZHU Ruifang, GUO Dongkai, ZHI Hui, JIANG Yiguo, ZHANG Yueling, QIAN Xiaoping, JI Shiliang. Exploring the mechanism of elemene synergistic bortezomib against multiple myeloma by ROS-NF-κB-p38MAPK pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1219-1226.
[4]	LI Fei, DING Huiqin, CHEN Mengjing. Isonlosinine induces autophagy of PC9 cells by ERK signaling pathway in lung cancer [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1235-1240.
[5]	SHI Dandan, SUN Yiyao, CHEN Xiaoqi, YANG Fangming, ZHANG Chuanlei, WANG Xinting, YUAN Changwei, CHEN Xinju. Curative effect of fuzheng xiaoliu granules in the treatment of primary liver cancer and analysis of serum metabolomics [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1247-1262.
[6]	LU Kepeng, LIU Caihong, BI Ying. Effect of prophylactic anticoagulation duration on venous thrombosis after total hip/knee arthroplasty [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1269-1274.
[7]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[8]	LIU Zhaofeng, LI Ling, NA Shufang, YUE Jiang, YE Qifa. Regulation mechanism of post-translational modification of farnesoid X receptor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1292-1298.
[9]	CHEN Yulin, JIANG Hugang, WANG Xinqiang, LIU Kai, LI Yingdong, AN Tao, ZHAO Xinke. Effects and mechanism of Ginseng Yixin granules (QSYXG) for heart failure with preserved ejection fraction based on the network pharmacology and molecular docking strategy [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1081-1092.
[10]	WANG Xiu, JI Qilin, PEI Wenjun, ZENG Ying. 3-bromopyruvate cholesterol ester enhances the sensitivity of breast cancer cells to tamoxifen [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1093-1100.
[11]	HENG Bingbing, YANG Danfeng, DAI Shuyang, SHANGGUAN Wangning. Propofol relieves the subcutaneous chloroquine-induced pruritus in rats via TRPV1 and CB1 receptors of spinal cord [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1101-1108.
[12]	JIA Boying, ZHOU Shuang, WAN Liyan, ZHOU Ying, CUI Yimin. Drug-induced dysphagia risk in elder people——A pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) database [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1109-1120.
[13]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[14]	LIU Min, KONG Xiang, ZHANG Ye, GU Yifei, XIANG Xuemei, HUANG Kai. Safety analysis on bioequivalence studies of orally inhaled drug products in healthy Chinese subjects#br# [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1131-1138.
[15]	LIAO Mengling, WANG Yan, LUO Jing, WANG Nuoyan, HUA Ling, ZHANG Yu, DENG Fei, YUAN Yue, ZHOU Jun, ZHOU Hong. Molecular mechanism of artesunate attenuates the release of proinflammatory cytokines from macrophages [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 969-978.